## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Typ	pe Response	s)															
1. Name and Address of Reporting Person * Ende Eric J					2. Issuer Name and Ticker or Trading Symbol Matinas BioPharma Holdings, Inc. [MTNB]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  X Director 10% Owner				
(Last) (First) (Middle) C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH, SUITE 302				$\log S$ , $0$	3. Date of Earliest Transaction (Month/Day/Year) 08/20/2019							Office	r (give title belo	ow)	Other (specify	below)	
(Street)				4	4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line)  Form filed by One Reporting Person Form filed by More than One Reporting Person						
BEDMINSTER, NJ 07921 (City) (State) (Zip)					Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned												
1.Title of Security (Instr. 3)			2. Transacti Date (Month/Day	y/Year) E	ıny		3. Transact Code (Instr. 8)		etion 4			uired of (D)	5. Amoun Beneficial Reported	ant of Securities ally Owned Following d Transaction(s)		6. Ownership Form:	Beneficial
				(1	Month/Day/		Co	de	V	Amoun	(A) or (D)	Price	,		\ /	Ownership (Instr. 4)	
Common Stock, par value \$0.0001 per share		08/20/20	19			F	•	2	20,000		\$ 0.66	109,292			D		
			Tal		erivative Se			t quire	the for d, Disp	rm dis	splays a o	currer eficiall	itly valid		spond unle trol numbe		
Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transactio Date (Month/Day/	3A. Deemed Execution Data	eemed ition Date,	4. te, if Transaction Code Year) (Instr. 8)		5.		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Ti Amo Unde Secu	r. 3 and	Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	Owners Form o Derivat Security Direct ( or Indir	Beneficia ive Ownersh (Instr. 4)	
					Code	V	(A)		Date Exerci		Expiratior Date	Title	Amount or Number of Shares				
Renor	ting O	wners			-												•

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Ende Eric J C/O MATINAS BIOPHARMA HOLDINGS, INC. 1545 ROUTE 206 SOUTH, SUITE 302 BEDMINSTER, NJ 07921	X					

# **Signatures**

/s/ Jerome D. Jabbour, attorney-in fact for Eric J. Ende	08/22/2019		
**Signature of Reporting Person	Date		

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.